Paydirt
RW
Insider

Robert E. Waltermire

Senior VP, Chief Pharma Dev. · Madrigal Pharmaceuticals

Robert E. Waltermire (Senior VP, Chief Pharma Dev.) filed 3 Form 4 reports in the past 24 months (0 purchases, 3 sales), most often in Madrigal Pharmaceuticals, Inc. (MDGL). The largest single filing was $4.8M of MDGL (14,113 sh across 9 lots, as filed), executed Mar 5 2025. Data as of Nov 8 2026.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$5.3M
shares × price, as filed
Last traded
Mar 5 2025
Filed Mar 7 2025

Median ADV $194.4M across their filed names

Open performance→
Volume by month
$5.2M$2.6M$0Dec 2024Jun 2025Dec 2025Jun 2026Jan 2025 · sells $121KMar 2025 · sells $5.2M
Buys $0 Sells $5.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 3 filings

Sector per market data · by filing · past 24 months

Most traded names
MDGL Madrigal Pharmaceuticals, Inc. MDGL · 0 buys · 3 sells 3 filings
Recent filings
MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $4.8M
14,113 sh across 9 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $359K
1,052 sh × $340.99
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET MDGLSALE Madrigal Pharmaceuticals, Inc. View filing → $121K
442 sh × $273.41
Exec Jan 17 2025
Filed Jan 17 2025 · 5:30 PM ET